Iqvia Holdings (IQV) stock price is $263.84, up 0.02% on the day, as of Nov 5, 2026. It has a market cap of $43.59Bn and a P/E ratio of 31.27, and is classified in the Contract Research industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap43.59 Bn
P/E31.27
FCF (Yr)2.05 Bn
ROA (Yr)4.79
EV to EBIT15.70
Net Income (Yr)1.36 Bn
Enterprise Value34.85 Bn
Add ratio to table…
About
IQVIA Holdings Inc. is a leading global provider of clinical research services commercial insights and healthcare intelligence to the life sciences and healthcare industries. The company delivers actionable insights and services built on high-quality health data Healthcare-grade AI advanced analytics the latest technologies and extensive domain expertise. With approximately 91000 employees in over 100 countries IQVIA is dedicated to accelerating the development and…
IQVIA Holdings Inc. is a leading global provider of clinical research services commercial insights and healthcare intelligence to the life sciences and healthcare industries. The company delivers actionable insights and services built on high-quality health data Healthcare-grade AI advanced analytics the latest technologies and extensive domain expertise. With approximately 91000 employees in over 100 countries IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA generates revenue primarily through the provision of its services across three operational segments. The company does not have any material product revenues. Its services include mission critical information technology solutions real world insights outsourced clinical research and clinical trial related services and health care provider and patient engagement services. These services are provided to life science clients biopharmaceutical customers and the broader healthcare market.
The company operates through the following segments: Technology & Analytics Solutions Research & Development Solutions and Contract Sales & Medical Solutions.
Technology & Analytics Solutions provides mission critical information technology solutions and real world insights and services to life science clients.
Research & Development Solutions provides outsourced clinical research and clinical trial related services primarily to biopharmaceutical customers.
Contract Sales & Medical Solutions provides health care provider including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market.
IQVIA holds a leading position in the global life sciences and healthcare industries as a provider of integrated analytics technology and clinical research services. The company competes with other firms in clinical research data analytics and healthcare consulting but differentiates itself through its extensive data assets advanced AI capabilities and global scale. Its competitive advantages include access to high-quality health data proprietary analytics platforms and deep domain expertise across the healthcare value chain.
IQVIA serves biotech medical device and pharmaceutical companies medical researchers government agencies payers and other healthcare stakeholders. The company’s customer base includes organizations across the life sciences and healthcare sectors seeking to advance drug development commercialization and patient care through data-driven insights and clinical execution capabilities.
Sectors:Healthcare·TechnologySector rationaleThe company's core business is providing outsourced clinical research, clinical trial services, and healthcare intelligence to biopharmaceutical and life science clients, which falls under Contract Research and Healthcare Services. A secondary sector of Technology is justified because the company operates a distinct 'Technology & Analytics Solutions' segment providing mission-critical IT solutions and proprietary AI analytics platforms as a substantial line of business.Industries:Contract ResearchContract ResearchPrimaryIQVIA operates a 'Research & Development Solutions' segment that provides outsourced clinical research and clinical trial related services to biopharmaceutical customers. This matches the description of a Contract Research Organization (CRO) that runs clinical development for drug and device sponsors.Healthcare ITHealthcare ITSecondaryThe company's 'Technology & Analytics Solutions' segment provides mission-critical information technology solutions and real-world insights specifically for life science clients, utilizing healthcare-grade AI and proprietary analytics platforms.Classified using BQ-MICSCIK: 0001478242
Bull & bear
Investment Thesis
▲ Bull case
IQVIA’s organic revenue growth is accelerating beyond what the market has priced in, with Commercial Solutions delivering 5% organic growth in Q1 FY26, double the prior year’s rate, and R&D Solutions achieving 3% organic growth, triple the prior year’s rate. This acceleration is driven by robust demand for AI‑enabled offerings that are already generating new service lines such as AI‑ready data foundations and agentic AI workflows, which management highlighted as expanding the scope of existing client partnerships. The company’s backlog reached a record $34.2 billion at quarter end, with $8.9 billion expected to convert to revenue over the next twelve months, representing 7.6% year‑over‑year growth and providing a visible runway for future earnings. These fundamentals suggest that the market is underestimating the durability of the growth engine built on AI integration and expanding client spend on analytics, consulting, and patient solutions.
Strategic collaborations announced after the earnings call reveal hidden catalysts that are not yet reflected in consensus estimates. The partnership with Kexing Biopharm to support a global biosimilar development program leverages IQVIA’s end‑to‑end capabilities, AI‑enabled trial execution, and regulatory expertise, positioning the company to capture a growing share of the biosimilar market as emerging market players seek international expansion. Simultaneously, the collaboration with the Duke Clinical Research Institute on obesity and cardiometabolic trials taps into a high‑growth therapeutic area where IQVIA already has deep expertise, having supported over 120 obesity trials and enrolled more than 90,000 patients. These alliances are likely to generate additional bookings and backlog conversion in the medium term, creating upside to the current guidance that assumes only modest acquisition contribution.
The company’s AI narrative is more than a marketing talking point; it is a structural shift that is creating new demand rather than cannibalizing existing services. Management noted that clients are launching more molecules because they use AI to identify additional targets, which will increase the number of trials and assets requiring CRO support. IQVIA’s deployment of 192 specialized life sciences AI agents across 64 use cases, with 19 of the top 20 pharma already utilizing them, demonstrates deep penetration and sticky integration into client workflows. This AI‑driven increase in outsourcing demand offsets concerns about AI replacing services and provides a multi‑year tailwind that the market appears to be discounting in favor of near‑term margin volatility.
Financial discipline and shareholder returns are strengthening the investment case beyond the earnings beat. IQVIA repurchased $552 million of stock in Q1 FY26 and increased its remaining repurchase authorization to $3.2 billion, signaling confidence in intrinsic value and providing a meaningful support level for the share price. Free cash flow reached $491 million in the quarter, representing 100% of adjusted net income and growing 15% year‑over‑year, which underscores the company’s ability to fund buybacks and debt reduction without sacrificing growth investments. The combination of strong cash generation, a leveraged but manageable balance sheet, and an expanding AI‑powered product suite creates a compounding effect that the market has not fully valued.
IQVIA’s organic revenue growth is accelerating beyond what the market has priced in, with Commercial Solutions delivering 5% organic growth in Q1 FY26, double the prior year’s rate, and R&D Solutions achieving 3% organic growth, triple the prior year’s rate. This acceleration is driven by robust demand for AI‑enabled offerings that are already generating new service lines such as AI‑ready data foundations and agentic AI workflows, which management highlighted as expanding the scope of existing client partnerships. The company’s backlog reached a record $34.2 billion at quarter end, with $8.9 billion expected to convert to revenue over the next twelve months, representing 7.6% year‑over‑year growth and providing a visible runway for future earnings. These fundamentals suggest that the market is underestimating the durability of the growth engine built on AI integration and expanding client spend on analytics, consulting, and patient solutions.
Strategic collaborations announced after the earnings call reveal hidden catalysts that are not yet reflected in consensus estimates. The partnership with Kexing Biopharm to support a global biosimilar development program leverages IQVIA’s end‑to‑end capabilities, AI‑enabled trial execution, and regulatory expertise, positioning the company to capture a growing share of the biosimilar market as emerging market players seek international expansion. Simultaneously, the collaboration with the Duke Clinical Research Institute on obesity and cardiometabolic trials taps into a high‑growth therapeutic area where IQVIA already has deep expertise, having supported over 120 obesity trials and enrolled more than 90,000 patients. These alliances are likely to generate additional bookings and backlog conversion in the medium term, creating upside to the current guidance that assumes only modest acquisition contribution.
The company’s AI narrative is more than a marketing talking point; it is a structural shift that is creating new demand rather than cannibalizing existing services. Management noted that clients are launching more molecules because they use AI to identify additional targets, which will increase the number of trials and assets requiring CRO support. IQVIA’s deployment of 192 specialized life sciences AI agents across 64 use cases, with 19 of the top 20 pharma already utilizing them, demonstrates deep penetration and sticky integration into client workflows. This AI‑driven increase in outsourcing demand offsets concerns about AI replacing services and provides a multi‑year tailwind that the market appears to be discounting in favor of near‑term margin volatility.
Financial discipline and shareholder returns are strengthening the investment case beyond the earnings beat. IQVIA repurchased $552 million of stock in Q1 FY26 and increased its remaining repurchase authorization to $3.2 billion, signaling confidence in intrinsic value and providing a meaningful support level for the share price. Free cash flow reached $491 million in the quarter, representing 100% of adjusted net income and growing 15% year‑over‑year, which underscores the company’s ability to fund buybacks and debt reduction without sacrificing growth investments. The combination of strong cash generation, a leveraged but manageable balance sheet, and an expanding AI‑powered product suite creates a compounding effect that the market has not fully valued.
Despite the upbeat commentary, management’s dismissal of margin impacts from the unusually low pass‑through mix in Q1 bookings may be evasive and could mask underlying profitability pressures. The CFO attributed 60 basis points of EBITDA margin contraction to FX and pass‑throughs, yet claimed that operational productivity programs fully offset the mix effect, implying that any future deterioration in the productivity environment would directly hurt margins. If the current favorable mix of lower pass‑through, full‑service trials proves temporary and the business reverts to a higher pass‑through profile, the lack of a built‑in margin buffer could lead to unexpected margin compression that the market is not anticipating.
The company’s high leverage remains a material risk that the market may be underweighting given the current focus on growth narratives. Net debt stood at $13.886 billion at the end of Q1 FY26, resulting in a net leverage ratio of 3.62x trailing twelve‑month adjusted EBITDA. While the balance sheet appears manageable today, any slowdown in cash flow conversion from the sizable backlog—particularly if the lag between EVP funding and trial awards extends beyond the assumed one‑to‑one‑and‑a‑half‑year horizon—could strain liquidity and limit the ability to sustain both aggressive share repurchases and continued investment in AI capabilities.
Organic growth rates, while improving, are still modest and may be overstated by the benefit of recent acquisitions and foreign exchange tailwinds. Commercial Solutions reported 11.6% revenue growth, but only 5% was organic after stripping out acquisitions and FX; R&D Solutions reported 6.2% reported growth with just 3% organic. This suggests that the underlying demand environment is still relatively tepid, and the company’s reliance on inorganic growth to boost top‑line performance could become a headwind if acquisition integration proves challenging or if valuation multiples for potential targets compress. The market may be overestimating the sustainability of the current growth acceleration without a corresponding increase in organic demand.
External macro and policy headwinds that have historically affected the life sciences outsourcing market remain present and could resurface, yet management’s characterization of the environment as merely stabilizing may downplay lingering risks. The Inflation Reduction Act, ongoing biotech funding volatility, potential tariff shifts, and evolving FDA regulations continue to create uncertainty around client capital allocation and trial initiation. While EVP funding reached $25 billion in Q1 FY26 per BioWorld, the conversion of that funding into backlog has a lag, and any reversal in funding trends would not be immediately visible in the company’s forward‑looking metrics. Investors may be ignoring the possibility that the current tailwind from policy‑driven funding is temporary and that a downturn could quickly erode the pipeline of future bookings.
Despite the upbeat commentary, management’s dismissal of margin impacts from the unusually low pass‑through mix in Q1 bookings may be evasive and could mask underlying profitability pressures. The CFO attributed 60 basis points of EBITDA margin contraction to FX and pass‑throughs, yet claimed that operational productivity programs fully offset the mix effect, implying that any future deterioration in the productivity environment would directly hurt margins. If the current favorable mix of lower pass‑through, full‑service trials proves temporary and the business reverts to a higher pass‑through profile, the lack of a built‑in margin buffer could lead to unexpected margin compression that the market is not anticipating.
The company’s high leverage remains a material risk that the market may be underweighting given the current focus on growth narratives. Net debt stood at $13.886 billion at the end of Q1 FY26, resulting in a net leverage ratio of 3.62x trailing twelve‑month adjusted EBITDA. While the balance sheet appears manageable today, any slowdown in cash flow conversion from the sizable backlog—particularly if the lag between EVP funding and trial awards extends beyond the assumed one‑to‑one‑and‑a‑half‑year horizon—could strain liquidity and limit the ability to sustain both aggressive share repurchases and continued investment in AI capabilities.
Organic growth rates, while improving, are still modest and may be overstated by the benefit of recent acquisitions and foreign exchange tailwinds. Commercial Solutions reported 11.6% revenue growth, but only 5% was organic after stripping out acquisitions and FX; R&D Solutions reported 6.2% reported growth with just 3% organic. This suggests that the underlying demand environment is still relatively tepid, and the company’s reliance on inorganic growth to boost top‑line performance could become a headwind if acquisition integration proves challenging or if valuation multiples for potential targets compress. The market may be overestimating the sustainability of the current growth acceleration without a corresponding increase in organic demand.
External macro and policy headwinds that have historically affected the life sciences outsourcing market remain present and could resurface, yet management’s characterization of the environment as merely stabilizing may downplay lingering risks. The Inflation Reduction Act, ongoing biotech funding volatility, potential tariff shifts, and evolving FDA regulations continue to create uncertainty around client capital allocation and trial initiation. While EVP funding reached $25 billion in Q1 FY26 per BioWorld, the conversion of that funding into backlog has a lag, and any reversal in funding trends would not be immediately visible in the company’s forward‑looking metrics. Investors may be ignoring the possibility that the current tailwind from policy‑driven funding is temporary and that a downturn could quickly erode the pipeline of future bookings.